Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)
Objective: To assess the safety, PK/PD, exploratory biomarkers, and efficacy of ANX005 in patients with, or at risk for, manifest HD. Background: Increased complement activation…Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease
Objective: In this study, we investigated the effects of SR9009, a Rev-ERB agonist, on the dopaminergic system in the MPTP model of PD. Background: Circadian…Safety and Tolerability of a Ketone Supplement in Parkinson’s Disease
Objective: To investigate the safety and tolerability of a high-dose exogenous ketone supplement in people with Parkinson’s Disease (PD). Background: Animal models and small pilot…Exploring the Potential Anti-dementia Roles of Selected Herbal Anti-inflammatory Remedies in Parkinson’s Disease: Hopes and Challenges
Objective: To evaluate anti-dementia properties of the selected herbal anti-inflammatory remedies Background: Parkinson’s disease (PD) is the most common age-related neurodegenerative disease after Alzheimer’s disease.…FIRST-IN-MAN CLINICAL TRIAL OF INTRAPUTAMENAL CDNF IN PARKINSON’S DISEASE FINDS A CONSORTED BIOMARKER RESPONSE IN A SUBGROUP OF SUBJECTS
Objective: In the first-in-man clinical study of intermittent intraputamenal monthly infusions of CDNF in subjects with moderately advanced PD, we explored cerebrospinal fluid (CSF) biomarkers…Tinospora Cordifolia protects against Rotenone induced degeneration of dopaminergic neurons in mouse model of Parkinson’s disease
Objective: To explore the neuroprotective mechanisms of T. cordifolia ethanolic extract against Rotenone (ROT)-intoxicated mouse model through proteomics approach. Background: The death of dopaminergic (DAergic)…Inhibition of GluN2D-containing NMDA receptors alleviates the loss of dopaminergic neurons and behavioral deficits in 6-OHDA-induced model of Parkinson’s disease
Objective: The aim of this study is to explore whether the inhibition of GluN2D-containing NMDA receptors (NMDAR2D) can delay the pathological manifestations of Parkinson's disease…CHAPERONIC PROPENSITIES OF AFRICAN WALNUT AS A THERAPEUTIC TARGET IN MANGANESE-INDUCED PARKINSON-LIKE NEUROPATHOLOGY IN WISTAR RATS
Objective: Herein, the chaperonic propensities of ethanolic extract of African walnut (WNE) in Manganese-induced Parkinson-like neuropathology in the prefrontal cortex and hippocampus was investigated. Background:…Pilot study of Phenotype of Antisense-Oligonucleotide-(ASO)-knockdown of Cerebral-Dopamine-Neurotrophic-Factor (CDNF) as Parkinson Disease model : implications for PD and related Dementia Therapeutics
Objective: Our objective is twofold: 1)to examine whether CDNF-ASO paradigm can induce a unique phenotype mimicking PD/PDD/LBW in the rodent species; 2) to evaluate whether…STATINS IN PARKINSON’S DISEASE: INFLUENCE ON MOTOR PROGRESSION
Objective: To evaluate whether long-term statin use may affect motor progression in a large cohort of de novo patients with Parkinson's Disease. Background: Statins are…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »